List of Medicines Access Programs (MAPs) and their respective characteristics in Australia and New Zealand in 2014-15. Medicine Brand name in Australia (Aus) and/or New Zealand (NZ) of centres status Indications covered Number of patients enrolled Patient (AUD) TGA status PBS status MAP Australia Medsafe NZ schedule MAP NZ Abiraterone Zytiga® Aus and NZ 6 No Metastatic prostate cancer 17 None March 2012 Listed Aug 2013 outside funding restrictions June 2013 Listed May 2015 no funding Afatanib Aus 7 Yes Epidermal Growth Factor Receptor positive non-small cell lung cancer 21 None Nov 2013 July 2015 no funding no registration no funding no registration Aflibercept Zaltrap® Aus 3 Yes In combination with based in eligible patients with metastatic colorectal cancer (mCRC) previously treated with an 7 None Feb 2012 PBAC July 2013 no funding Dec 2014 no funding no no funding , rejected -
Arsenic Trioxide Aus and NZ 6 Yes First line treatment of acute leukaemia 6 and first two cycles can cost the patient May 2009, first-line Aug 2015 PBS-listed second line for acute leukaemia (March 2019), first line Nov 2015 outside funding restrictions July 2013 unknown Azacitidine Vidaza® Aus and NZ 6 Yes syndromes 6 The patient had to fund the first two cycles and was at to the patient Nov 2009 Listed Feb 2011 outside funding restrictions May 2010 Sept 2014 outside funding restrictions Bendamustine Aus 5 Yes No response 2 No June 2014 in March 2015, listed April 2016 no no funding May 2015 no funding no no funding registration , , deferred
registration Crizotinib Xalkori® Aus and NZ 14 Yes ALK+ cell lung cancer 29 Up to $100 per month for fees Sept 2013 PBS listed July 2015 no funding Feb 2015 no funding no no funding Dafrafenib Rafinlar® Aus and NZ 11 Yes Metastatic melanoma; BRAF V600 mutant 102 None Aug 2013 July 2013 outside funding restrictions no no funding no registration Denosumab Xgeva® Aus and NZ 4 Yes refractory skeletal metastases 6 None Sept 2011 Not listed for this indication outside funding restrictions May 2012 no funding no funding Enzatulamide Xtandi® Aus and NZ 4 Yes Metastatic prostate cancer 6 None July 2014 July 2014 listed Dec 2014 no no funding May 2015 no funding no no funding Eribulin Halaven® Aus 1 No No response 0 No Aug 2012 Listed for metastatic breast cancer outside funding restrictions no no funding no registration small
Erlotinib Tarceva® Aus 8 No Metastatic non-small cell lung cancer and pancreatic cancer 0 None Jan 2006 2013 March 2014 (mNSCLC without ECFR mutation), never for pancreatic cancer outside funding restrictions Dec 2011 Jan 2014 outside funding restrictions Everolimus Afinitor® Aus and NZ 19 Yes Metastatic breast cancer; primitive tumour 68 None (first in 2005) for mRCC, pNET, nNET, mBC, SEGA PBS-listed for mRCC, pNET, tuberous sclerosis complex, mBC outside funding restrictions Sept 2009 Nov 2014 for SEGA outside funding restrictions
registration Fulvestrant Aus and NZ 11 Yes Oestrogen positive metastatic breast cancer 20 First 2 doses free, next 3 doses paid by then patient, then all free March 2006 no funding no funding May 2006 no funding no funding Gefitinib Iressa® Aus 2 No No response 0 No April 2003 July 2004 first line July 2013 outside funding restrictions Jan 2004 Aug 2012 outside funding restrictions Ibrutinib Aus and NZ 18 Yes Relapsed or refractory mantle cell lymphoma; chronic lymphocytic leukaemia; small lymphocytic lymphoma 44 None April 2015 for chronic leukaemia and lymphoma July 2015 (deferred Nov 2015) no no funding July 2015 no funding no registration rejected
Idelalisib* Zydelig® Aus 4 Yes Chronic lymphocytic leukaemia; small lymphocytic lymphoma; follicular lymphoma 29 None Feb 2015 no funding no no funding Feb 2016 no funding no registration Imatinib Glivec® Aus and NZ 10 Yes stromal tumours; case by case application made to the company 13 None June 2009 in Nov 2009, July 2010, approved in March 2011 extension in March 2012, approved in Nov 2012 outside funding restrictions July 2010 April 2014 outside funding restrictions Ipilimumab Yervoy® Aus and NZ 6 Yes Metastatic melanoma 38 None July 2011 Nov 2012, listed in August 2013 outside funding restrictions March 2012 no funding no funding
Lenalidomide Aus and NZ 13 Yes Multiple myeloma 23 None Dec 2007 Nov 2008, extension in Nov 2015 outside funding restrictions Oct 2008 Sept 2014 outside funding restrictions Lenvatinib Aus and NZ 3 Yes thyroid cancer 3 None Jan 2016 no funding no registration no no funding no registration Nilotinib Tasigna® Aus and NZ 11 Yes Chronic myeloid leukaemia 6 None Jan 2008 in March 2008 outside funding restrictions August 2010 Oct 2014 outside funding restrictions Nintedanib Ofev® Aus 2 Yes Non-small cell lung cancer 6 None Sept 2015 in March 2015 and March 2016 no registration March 2016 no funding no registration Nivolumab* Opdivo® Aus and NZ 17 Yes Metastatic melanoma; metastatic non-small cell lung cancer; metastatic renal cell cancer; classical Hodgkins lymphoma 110 None Feb 2016 no funding no registration April 2016 no funding no registration resistant
registration Obinutuzumab Gazyva® Aus and NZ 4 Yes Diffuse large B-cell lymphoma 1 None No for the No PBAC application no registration no for this no funding no registration Ofatumumab Arzerra® Aus and NZ 2 Yes No response 1 None Sept 2014 for CLL in Nov 2014 no no funding no no funding no registration Olaparib Aus and NZ 3 Yes Breast cancer; stage 4 papillary serous carcinoma (BRCA1 mutation positive) 3 None Dec 2015 no funding no registration Nov 2016 no funding no registration Paclitaxel nanoparticle Aus and NZ 11 Yes Metastatic pancreatic cancer second line 93 $463 per vial for the first 21 vials March 2014 March 2014, listing Nov 2014 no no funding no funding no no funding Panitumumab Vectibix® Aus and NZ 5 Yes Metastatic colorectal cancer 2 None May 2008 for mCRC in 2013/2014 and extended March 2015 outside funding restrictions no no funding no registration
Pazopanib Votrient® Aus and NZ 10 Yes Renal cell carcinoma; soft tissue sarcoma 8 None June 2010 for renal cell Nov 2012 for soft tissue March 2012 (renal cell July 2013 (soft tissue sarcoma) outside funding restrictions Sept 2010 April 2012 for mRCC outside funding restrictions Aus and NZ 15 Yes Ipilimumab treated or metastatic melanoma patients ; advanced gastric cancer 36 Cost varied as per 2015 listed for netastatic melanoma July 2015 no no funding Sept 2015 listed Sept 2016 no registration
registration Pertuzumab Perjeta® Aus and NZ 21 Yes Metastatic breast cancer (HER2 positive) in combination with trastuzumab and docetaxel in patients who have not received prior treatment or 61 None There were in the past May 2013 listed July 2015 no funding July 2013 listed Dec 2016 no funding Plerixafor Mozobil® Aus 2 No No response 0 No May 2010 Nov 2013 outside funding restrictions May 2015 listed Sept 2016 no registration Pomalidomide Aus and NZ 12 Yes Relapsed refractory multiple myeloma 16 Patient paid for up to 2 cycles July 2014 Nov 2014, listed Aug 2015 no no funding March 2015 no funding no no funding
Ponatinib Iclusig® Aus 7 Yes Accelerated phase chronic myeloid leukaemia or intolerant to prior tyrosine kinase inhibitor; Philadelphia positive acute leukaemia resistant or intolerant to prior tyrosine kinase inhibitor 2 Cost capped at $23,000 Nov 2014 July 2015 no no funding no no funding no registration Regorafenib Stivarga® Aus and NZ 9 Yes stromal tumour; metastatic colorectal cancer 23 $500 per month for first 12 months then free Nov 2013 for mCRC, March 2015 for GIST July 2014 and March 2015 no no funding Sept 2014 no funding no no funding
Sorafenib Aus and NZ 4 Yes Various cancers with vascular endothelial growth factor as feature 11 None Sept 2006 July 2008 (liver in March 2014, March 2015 and November 2015 for thyroid several times for renal cell carcinoma and in Nov 2014 outside funding restrictions May 2007 no funding no funding Sunitinib Sutent® Aus 2 No No response 0 No Sept 2006 Aug 2013 (pNET), July 2008 (RCC), July 2009 (GIST) outside funding restrictions Oct 2006 listed GSIT Nov 2012, listed mRCC Nov 2010 outside funding restrictions
Temozolomide Aus and NZ 6 Yes 7 None June 1999 PBS-listed for multiforme outside funding restrictions Dec 1998 April 2006 outside funding restrictions Temsirolimus Torisel® Aus 4 Yes Metastatic renal cell carcinoma 22 None June 2008 in July 2008 no funding no no funding no registration Trabectedin Aus 2 No Soft tissue sarcoma 0 None not sponsor No PBAC application no registration no no funding no registration Trametinib Mekinist® Aus and NZ 24 Yes In combination with dabrafenib for treatment of BRAF V600 mutation positive Stage 3 or metastatic melanoma 106 None Feb 2014 March 2014, Nov 2014 no funding March 2015 no funding no no funding
Trastuzumab emtansine Kadcyla® Aus and NZ 18 Yes HER2+ metastatic breast cancer in combination with trastuzumab and docetaxel in patients who did not receive prior anti-HER2 treatment or 22 None Sept 2013 March 2014, listed July 2015 no funding Sept 2013 no funding no funding Vemurafenib Zelboraf® Aus 9 Yes Metastatic BRAF positive melanoma 23 None May 2012 March 2013, in with March 2016 no funding Dec 2015 no funding no registration